Listen on the go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Biree Andemariam

    University of Connecticut Health, Farmington, CT, USA

    Prof. Andemariam is professor of medicine and the American Red Cross Endowed Chair at the University of Connecticut School of Medicine, CT, USA. She is a physician scientist in the Division of Hematology/Oncology, founding director of the New England Sickle Cell Institute and director of the Connecticut Bleeding Disorders Center. read more

    Prof. Andemariam has been lead principal investigator of several global sickle cell disease clinical trials and registry studies. Her research interests include defining the intracellular signalling pathways involved in sickle vaso-occlusion and developing/implementing care pathways that lead to improved patient outcomes and health resource utilization.

    Disclosures

    Prof. Biree Andemariam discloses: Grants/research support from Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk and Pfizer. Consulting fees from Accordant, Emmaus (Relationship Terminated) and GlaxoSmithKline. Advisory board or panel fees from Afimmune, Agios Pharmaceuticals, Bluebird Bio, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Pfizer, Sanofi Genzyme and Vertex Pharmaceuticals.
    Prof. Modupe Idowu

    University of Texas Health Science Center, McGovern Medical School, Houston, TX, USA

    Prof. Idowu is professor of medicine in the Division of Hematology at the University of Texas (UT) Health Science Center, McGovern Medical School in Houston, TX, USA. She is the director of the Division of Hematology, associate programme director of the Hematology/Oncology Fellowship and medical director of UT Physicians Comprehensive Sickle Cell Center. read more

    Prof. Idowu is an active member of the American Society of Hematology, American Federation for Medical Research and the National Medical Association. Her clinical interests include sickle cell anaemia, other anaemias, thrombocytopenia, leukopenia and bone marrow disorders. In addition to serving as principal investigator for more than 12 clinical trials, Prof. Idowu is also a reviewer for numerous scientific journals.

    Disclosures

    Prof. Modupe Idowu discloses: Grants/research support from Agios Pharmaceuticals, Alexion, Forma, Global Blood Therapeutics, Novartis, Novo Nordisk and Pfizer. Consulting fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Advisory board or panel fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Speaker’s bureau fees from Global Blood Therapeutics.
    Prof. Mark C Walters

    University of California, San Francisco, Oakland, CA, USA

    Prof. Walters is the Jordan Family Director of the Blood and Marrow Transplantation Program at University of California San Francisco (UCSF) Benioff Children’s Hospital, Oakland, CA, USA. He is professor and chief of the Hematology Division in the Department of Pediatrics at UCSF School of Medicine, and is programme director of the California Institute of Regenerative Medicine Alpha Stem Cell Clinic at UCSF. read more

    Prof. Walters is active in cooperative clinical transplantation trials and has led several National Institutes of Health-supported investigations of haematopoietic cell transplantation for sickle cell anaemia and thalassaemia. His research interests include haematopoietic cell transplantation for haemoglobin disorders, novel cellular therapies for non-malignant haematological disorders, and the use of genomic editing and gene addition therapies as a strategy to extend curative therapy in patients with a clinically significant haemoglobinopathy.

    Disclosures

    Prof. Mark C Walters discloses: Consulting fees from AllCells and BioChip Labs. Advisory board or panel fees from Ensoma and Vertex Pharmaceuticals.
    touchRESPIRATORY touchRESPIRATORY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Respiratory Intensive Care

    An Introduction to Respiratory Intensive Care

    Respiratory intensive care has been at the forefront of the COVID-19 pandemic, bringing with it many challenges. Intensive care has seen numerous important advances over recent years, including technological developments and improved monitoring systems and improvements in pharmacotherapies.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities

    Respiratory Intensive Care Content

    Lung Health, Respiratory Infections, Paediatric Respiratory Medicine, Respiratory Intensive Care
    Watch Time: 39 mins
    touchPANEL DISCUSSION
    Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
    CE/CME ACCREDITED Prof. Biree Andemariam, Prof. Modupe Idowu, Prof. Mark C Walters

    Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

    Learning objectives
    Learning Objectives
    • Summarize the various manifestations and multiple complications of SCD
    • Appraise the practical considerations for the multidisciplinary management of SCD complications
    • Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
    Respiratory Intensive Care, Sleep Related Breathing Disorders
    Margaret Pisani: Research Highlights from 2021

    We were delighted to speak with our editorial board member Professor Margaret Pisani (Yale University School of Medicine, New Haven, CT, USA) around this year’s research highlights in pulmonary, critical care and sleep medicine and what to look out for in 2022. Questions What are the key clinical highlights from 2021 in the field of […]

    Respiratory Intensive Care
    Wayne Anderson, ATS 2021: BIO­‑11006 in Patients with Acute Respiratory Distress Syndrome

    It was a pleasure to meet with Dr Wayne Anderson (UNC School of Medicine, Chapel Hill, NC, US) to discuss his recent study evaluating the safety and tolerability of BIO­‑11006 in patients with acute respiratory distress syndrome. ‘A Phase II, Placebo‑Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO­‑11006 Inhalation Solution in […]

    Respiratory Intensive Care
    Wayne Anderson, ATS 2021: Targeting the MARCKS Protein in Respiratory Disease

    It was a pleasure to meet with Dr Wayne Anderson (UNC School of Medicine, Chapel Hill, NC, US) to discuss his recent study evaluating the safety and tolerability of BIO­‑11006 in patients with acute respiratory distress syndrome. ‘A Phase II, Placebo‑Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO­‑11006 Inhalation Solution in […]

    Respiratory Intensive Care
    Improvement of Chest Wall Compliance Immediately Following Subcutaneous Placement of Central Venous Catheter for Decompression of Massive Subcutaneous Emphysema
    Erich Burton, Antine E Stenbit

    US Respiratory and Pulmonary Diseases. 2020;5(1):48-51 DOI: https://doi.org/10.17925/USPRD.2020.5.1.48

    Subcutaneous emphysema (SE) is relatively common in the intensive care unit (ICU) and often a complication of positive pressure ventilation.1,2 While typically self-limiting and benign, life-threatening sequela can develop. Progressive accumulation of subcutaneous air can result in significant compressive forces leading to the development of a rare clinical entity known as massive subcutaneous emphysema (MSE). The […]

    Respiratory Intensive Care, Ventilation
    Benjamin Seeliger, ERS 2019 – Veno-venous Extracorporeal Membrane Oxygenation Therapy in Acute Respiratory Distress Syndrome

    Benjamin Seeliger, Hannover, Germany, spoke to us at ERS 2019 in Madrid about the EOLIA trial and ECMO in veno-venous extracorporeal membrane oxygenation therapy. Questions 1. What is known about the effectiveness of extracorporeal membrane oxygenation (ECMO) in respiratory failure? (0:05) 2. What are the major challenges in designing clinical trials to investigate the utility […]

    Respiratory Intensive Care
    Mathematical and Computational Modelling in Critical Illness
    Marianna Laviola, Declan G Bates, Jonathan G Hardman

    European Respiratory & Pulmonary Diseases. 2019; 5(1):12–3.

    Life-threatening pulmonary illness is one of the most important reasons for admission to an intensive care unit (ICU). Such illnesses frequently require the use of tracheal intubation, deep sedation and mechanical ventilation. Although mechanical ventilation may keep a patient alive (by ensuring adequate gas exchange), it may lead to further lung injury, may contribute to […]

    Respiratory Intensive Care
    Jacqueline Kruser, ATS 2019 – Quality of End-of-Life Care in the Intensive Care Unit

    At the 2019 ATS conference in Dallas, TX, USA, Jacqueline Kruser (Northwestern University, Chicago, IL, USA) discusses the knowledge gap in end-of-life (EOL) care and the implications of her study findings in terms of meeting unmet needs in EOL care in patients in the ICU. Questions 1. What is currently known about end-of-life (EOL) care […]

    Respiratory Intensive Care
    Margaret Pisani, ATS 2019 – Delirium in the ICU

    Margaret Pisani (Yale University School of Medicine, New Haven, CT, USA) speaks from the 2019 ATS conference in Dallas, TX, USA about the impact of delirium in the intensive care unit (ICU) and new evidence on the potential benefits of pharmacological interventions to manage delirium. She also discusses the unmet needs for ICU patients with […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchRESPIRATORY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup